Slimming Breakthrough: White House Unveils Plan to Slash Weight Loss Drug Costs

**White House Announces Deal to Significantly Lower Weight Loss Drug Prices**

Slimming Breakthrough: White House Unveils Plan to...

Washington D.C. – In a move hailed as a victory for American patients, the Trump administration announced Thursday that it has brokered deals with pharmaceutical giants Novo Nordisk and Eli Lilly to drastically reduce the cost of GLP-1 drugs, a class of medications used to treat obesity, diabetes, and related cardiometabolic conditions. The agreement promises to make these life-changing drugs more accessible to millions, particularly those enrolled in Medicare.

The public-private partnership, dubbed TrumpRx, will

The public-private partnership, dubbed TrumpRx, will allow patients using the service to purchase a month's supply of injectable GLP-1 drugs for approximately $350. This price is projected to decrease further to $250 within two years for individuals paying entirely out-of-pocket, without insurance coverage. For those utilizing daily pill versions of the drugs, pending FDA approval, prices are expected to begin at $150 for starting doses, according to senior administration officials.

President Trump, speaking from the Oval Office, lauded the agreement as a significant achievement. "This is a triumph for American patients that will save lives and improve the health of millions and millions of Americans," he stated, thanking the pharmaceutical companies for their cooperation.

The deal is expected to broaden eligibility for these medications, particularly within Medicare. Individuals with severe obesity will soon be able to access GLP-1 drugs under Medicare, with a co-pay of $50. The new pricing structure could be implemented as early as mid-2026. Medicaid pricing and implementation will vary by state, as states opt into the program.

Currently, federal insurance programs cover Novo

Currently, federal insurance programs cover Novo Nordisk's Wegovy for overweight individuals with heart disease. However, Medicare does not currently cover any medications solely for obesity. The administration highlighted the significant cost disparity between the U.S. and other countries, noting that Americans have been paying substantially more for these drugs than patients in Europe.

"Until now, neither of these two popular drugs have been covered by Medicare for weight loss and they've only rarely been covered by Medicaid," Trump said. "They've often cost consumers more than $1,000 per month and some a lot more than that. Americans have been spending as much as 520% for Zepbound and 1,400% more for Wegovy than patients in Europe."

This agreement is the latest in the Trump administration's series of "most favored nations" agreements aimed at lowering drug prices for Americans. It follows an executive order signed in May directing the administration to pursue such deals. The announcement represents a significant step towards making crucial medications more affordable and accessible to a wider segment of the population.